Clinical trial · Interventional
Neoadjuvant Chemoimmunotherapy Followed by Surgery and Postoperative Radioimmunotherapy
Neoadjuvant Chemoimmunotherapy Followed by Surgery and Postoperative Radioimmunotherapy in Patients With Locally Advanced Esophageal Squamous Cell Carcinoma
NCT06602843CI-TRIAL-00080668recruitingN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The goal of this study was to explore the efficacy and safety of neoadjuvant chemoimmunotherapy followed by surgery and postoperative radioimmunotherapy in patients with locally advanced esophageal squamous cell carcinoma
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Esophageal Squamous Cell Carcinoma | Esophageal Squamous Cell Carcinoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Neoadjuvant chemoimmunotherapy followed by surgery and postoperative radioimmunotherapy | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Experimental
- description
- Neoadjuvant chemoimmunotherapy followed by surgery and postoperative radioimmunotherapy
- interventionNames
- Procedure: Neoadjuvant chemoimmunotherapy followed by surgery and postoperative radioimmunotherapy
- type
- ACTIVE_COMPARATOR
- label
- Comparator
- description
- chemoradiotherapy followed by surgery
- interventionNames
- Procedure: Neoadjuvant chemoimmunotherapy followed by surgery and postoperative radioimmunotherapy
Primary outcomes (1)
- measure
- pCR
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: * Ages 18-75; * Radical operation for esophageal cancer; * Esophageal squamous cell carcinoma was confirmed by postoperative pathology; . Preoperative imaging (enhanced cervical, thoracoabdominal CT+ bone scan) and postoperative pathological evaluation were performed, and the stage was pIIB-IVA (AJCC eighth edition staging criteria: T≥3 or N+). * More than or equal to 12 lymph nodes were surgically removed; * Postoperative ECOG score 0-1, able to tolerate postoperative adjuvant radiotherapy and immunotherapy; * Informed consent signed by patient or family member. Exclusion Criteria: * Less than 18 years old, more than 75 years old; * did not receive radical resection of esophageal cancer, including palliative resection; * Postoperative pathology showed non-esophageal squamous cell carcinoma; * After preoperative imaging (enhanced cervical, thoracoabdominal CT+ bone scan) and postoperative pathological evaluation, the stage was pI, IIA, IVB (AJCC eighth edition staging standard); e. Less than 12 lymph nodes were surgically removed; * Postoperative ECOG score 2-3 points, unable to tolerate postoperative adjuvant radiotherapy and immunotherapy; * The patient or family member did not sign the informed consent.
References
Publications (0)
Data not yet available
No reference posted for this study.